A Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer

Sponsor
Chinese Academy of Medical Sciences
Study ID
NCT03199677
Phase
PHASE2
Status
Unknown

Conditions

  • Refractory Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib is an oral tyrosine kinase inhibitor.

Study Details

This is a single-center, open-label, single arm，exploratory clinical trial evaluating the efficacy and safety of Apatinib in patients with local progressive/metastatic refractory thyroid cancer.

Key Dates

Start date
Jul 1, 2017
Status verified
Jun 2017
Primary completion
Jun 30, 2018
Completion
Jun 30, 2018

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: apatinib with 500mg qd po
    Patients administrate apatinib with the dose of 500mg once per day,half an hour after a meal.

Primary Outcome Measure

objective response rate [ Time Frame: 1 year ]

Central Contacts

Related Studies